Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Securities Fraud Investigation

Whistleblower Complaint filed against Madrigal
On November 3, 2026, Madrigal disclosed in its quarterly report that on October 9, 2026, the company’s former Senior Vice President and Head of Clinical Development filed a whistleblower complaint against Madrigal alleging that he reported to Madrigal’s Senior Executive Leadership “adverse safety findings and unreproducible efficacy data” for the company’s only approved drug, Rezdiffra. Specifically, “that Madrigal was suppressing adverse liver-injury data, presenting efficacy results that could not be reconciled with their own source data, and allowing an unblinded Board member… to control the adjudication of clinical outcomes.”

Madrigal’s Stock Drops Over 8%
Following the news of the whistleblower complaint against Madrigal, the company’s stock price fell over 8%.

If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at [email protected].  

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: 
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal’s Plaintiff’s Hot List and Trailblazers in Plaintiffs’ Law, BTI Consulting Group’s Honor Roll of Most Feared Law Firms, The Legal Intelligencer’s Class Action Firm of the Year, Lawdragon’s Leading Plaintiff Financial Lawyers, and Law360’s Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over $25 billion for our clients and the classes they represent.